Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House eyes FDA technology and resources

Executive Summary

Even before the fiscal year 2009 budget is proposed, the House Energy and Commerce Oversight Subcommittee is beginning to assess FDA resources. A November report from an FDA Science Board subcommittee decries weaknesses in the agency's regulatory science and inadequate scientific expertise. FDA Commissioner Andrew von Eschenbach, General Accounting Office officials and Science Board members are among those scheduled to testify at the Jan. 29 hearing to address the report, which claims resources are key to reversing FDA's scientific decline (1"The Pink Sheet" Dec. 10, 2007, p. 15)...

You may also be interested in...

What Does AERS Mean? FDA Takes A Close Look At Spontaneous Reporting

Amid a flurry of recent drug safety initiatives, FDA is not losing sight of the importance of spontaneous adverse event reporting. In fact, the agency is taking steps to evaluate and improve its passive surveillance system, which it expects to remain the cornerstone of its drug safety oversight

FDA Should Look Through IIRIS To Improve Science, Panel Says; Funding Is Worry

Increasing developments in emerging sciences, such as personalized medicine, could reach roadblocks at FDA where limited resources for specialized personnel and advanced equipment may inhibit research, a report from FDA's Science Board's Subcommittee on Science and Technology shows

Don’t Believe The Lack Of Hype: US Drug Price Reform Is Biggest Ever

The narrative about the Democrats’ march toward comprehensive drug pricing legislation in the US has emphasized what has dropped out of the original proposal. That obscures the bigger picture: it will be by far the most impactful drug pricing legislation ever enacted in the US.

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts